S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY

Autor: Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck Emmanuel Nicolini, Henrik Hjorth-Hansen, Antonio Almeida, Jeroen J. W. M. Janssen, Jiri Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson-Strömberg, Joaquín Martinez-Lopez, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Katerina Machova Polakova, Satu Mustjoki, Marc Berger, Andreas Hochhaus, Markus Pfirrmann, Susanne Saussele

Publikováno v: HemaSphere, Vol 7, p e0972454 (2023)

Externí odkaz: https://doaj.org/article/a078e335813f413cb617882efe61628c

Tool evaluation for the detection of variably sized indels from next generation whole genome and targeted sequencing data.

Autor: Ning Wang, Vladislav Lysenkov, Katri Orte, Veli Kairisto, Juhani Aakko, Sofia Khan, Laura L Elo

Publikováno v: PLoS Computational Biology, Vol 18, Iss 2, p e1009269 (2022)

Insertions and deletions (indels) in human genomes are associated with a wide range of phenotypes, including various clinical disorders. High-throughput, next generation sequencing (NGS) technologies enable the detection of short genetic variants, su

Externí odkaz: https://doaj.org/article/a437cab2e4244fe1ade8f6b8eae33a05

Variant calling tool evaluation for variable size indel calling from next generation whole genome and targeted sequencing data

Autor: Sofia Khan, Katri Orte, Vladislav Lysenkov, Ning Wang, Juhani Aakko, Veli Kairisto, Laura L. Elo

Insertions and deletions (indels) in human genomes are associated with a wide range of phenotypes, including various clinical disorders. High-throughput, next generation sequencing (NGS) technologies enable detection of short genetic variants, such a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::032f8776eed7705173ce3fec2a43d878
https://doi.org/10.1101/2021.07.15.452444

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

Autor: Anna Kreutzman, Peter Rohon, Edgar Faber, Karel Indrak, Vesa Juvonen, Veli Kairisto, Jaroslava Voglová, Marjatta Sinisalo, Emília Flochová, Jukka Vakkila, Petteri Arstila, Kimmo Porkka, Satu Mustjoki

Publikováno v: PLoS ONE, Vol 6, Iss 8, p e23022 (2011)

Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-α) was the treatment of choice in chronic myeloid leukemia (CML). Curiously, some IFN-α treated patients were able to discontinue therapy without disease progression. The ai

Externí odkaz: https://doaj.org/article/6dd371f4b6b64bb396523e3f23e118ab

Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia

Autor: Jonas Abrahamsson, Hans Beier Ommen, Helen Vålerhaugen, Kirsi Jahnukainen, Birgitte Lausen, Linda Fogelstrand, Sofie Johansson Alm, Christiane Walter, Bernward Zeller, Veli Kairisto, Nils von Neuhoff, Dirk Reinhardt, Henrik Hasle, Charlotte Guldborg Nyvold, Kristian Løvvik Juul-Dam

Publikováno v: Juul-Dam, K L, Ommen, H B, Nyvold, C G, Walter, C, Vålerhaugen, H, Kairisto, V, Abrahamsson, J, Alm, S J, Jahnukainen, K, Lausen, B, Reinhardt, D, Zeller, B, von Neuhoff, N, Fogelstrand, L & Hasle, H 2020, ' Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia ', British Journal of Haematology, vol. 190, no. 2, pp. 198-208 . https://doi.org/10.1111/bjh.16560
Løvvik Juul-Dam, K, Ommen, H B, Nyvold, C G, Walter, C, Vålerhaugen, H, Kairisto, V, Abrahamsson, J, Johansson Alm, S, Jahnukainen, K, Lausen, B, Reinhardt, D, Zeller, B, Von Neuhoff, N, Fogelstrand, L & Hasle, H 2018, ' Measurable Residual Disease Assessment By qPCR in Peripheral Blood Is an Informative Tool for Disease Surveillance in Childhood Acute Myeloid Leukemia ', American Society of Hematology: 60th Annual Meeting (ASH), San Diego, USA, 29/11/2018-04/12/2018 . < https://ash.confex.com/ash/2018/webprogram/Paper119642.html >
Løvvik Juul-Dam, K, Ommen, H B, Nyvold, C G, Walter, C, Vålerhaugen, H, Kairisto, V, Abrahamsson, J, Johansson Alm, S, Jahnukainen, K, Lausen, B, Reinhardt, D, Zeller, B, Von Neuhoff, N, Fogelstrand, L & Hasle, H 2018, ' Measurable Residual Disease Assessment By qPCR in Peripheral Blood Is an Informative Tool for Disease Surveillance in Childhood Acute Myeloid Leukemia ', Blood, vol. 132, no. Suppl. 1 . https://doi.org/10.1182/blood-2018-99-119642

Background: Relapse remains a serious event and main obstacle to permanent cure in childhood acute myeloid leukemia (AML). Reduction of measurable/minimal residual disease (MRD) assessed by real-time quantitative PCR (qPCR) during therapy is predicti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353c0fd987a10286297c8b440ff07aca
https://pubmed.ncbi.nlm.nih.gov/32191348